A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Refractory B-cell Acute Lymphoblastic Leukemia Clinical Trial

Official title:
A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Status Withdrawn

Clinical Trial Summary

To find a recommended dose of mosunetuzumab that can be given to patients with ALL.

Clinical Trial Description

Primary Objectives: --To assess the safety of mosunetuzumab in patients with R/R B-ALL Secondary Objectives: --To assess rate of CR/CRi, duration of response (DOR), progression-free survival (PFS) and overall survival (OS) of mosunetuzumab in patients with R/R B-ALL ;

Study Design

Related Conditions & MeSH terms

Leukemia
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Refractory B-cell Acute Lymphoblastic Leukemia

Clinical Trial Details

NCT number	NCT05961696
Study type	Interventional
Source	M.D. Anderson Cancer Center
Contact
Status	Withdrawn
Phase	Phase 1
Start date	July 5, 2023
Completion date	October 3, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03156101` - A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects	Phase 1/Phase 2
Completed	`NCT02808442` - Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia	Phase 1
Withdrawn	`NCT02167360` - Study of Efficacy and Safety of CTL019 in Adult ALL Patients	Phase 2
Recruiting	`NCT06179524` - CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL	Phase 2
Completed	`NCT02228096` - Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients	Phase 2